TROPHY-U-01 Cohort 4 (C4): Sacituzumab govitecan (SG) in combination with cisplatin (cis) as first-line (1L) therapy, followed by maintenance avelumab plus (+) SG or zimberelimab (zim) + SG in patients (pts) with treatment (Tx)-naïve metastatic urothelial cancer (mUC).

Authors

Chethan Ramamurthy

Mays Cancer Center, Philadelphia, PA

Chethan Ramamurthy , Alejandro Recio-Boiles , Petros Grivas , Umang Swami , Yohann Loriot , Julia Tonelli , Mitch Sierecki , Philippe Barthélémy

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

TROPHU-U-01 cohort 5: Evaluation of maintenance sacituzumab govitecan (SG) plus zimberelimab (ZIM), ZIM, or avelumab in cisplatin-eligible patients (pts) with unresectable or metastatic urothelial cancer (mUC).

First Author: Thomas Powles

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

TROPHY-U-01 cohort 6: Sacituzumab govitecan (SG), SG plus zimberelimab (ZIM), SG plus ZIM plus domvanalimab (DOM), or carboplatin (CARBO) + gemcitabine (GEM) in cisplatin-ineligible patients (pts) with treatment-naive metastatic urothelial cancer (mUC).

First Author: Ignacio Duran

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Safety analysis by UGT1A1 status of TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI).

First Author: Yohann Loriot

insert_chart_outlined

Poster

2022 ASCO Genitourinary Cancers Symposium

bookmark_border

TROPHY-U-01 cohort 4: Sacituzumab govitecan (SG) in combination with cisplatin (Cis) in platinum (PLT)-naïve patients (pts) with metastatic urothelial cancer (mUC).

First Author: Scott T. Tagawa